Maxygen Appoints John G. Curd, M.D., Senior Vice President, Clinical Development

Also Announces Other Key Additions to Company's Growing Clinical Team



Apr 12, 2001, 01:00 ET from Maxygen, Inc.

    REDWOOD CITY, Calif., April 12 /PRNewswire/ --
 Maxygen, Inc. (Nasdaq:   MAXY) today announced the appointment of John G. Curd,
 M.D., to the newly created position of Senior Vice President, Clinical
 Development.  Dr. Curd brings extensive protein pharmaceutical and vaccine
 development expertise to the company, and will oversee clinical development
 and medical affairs at Maxygen.  Maxygen also announced the appointments of
 Steven Glazer, M.D., to the position of Director, Clinical Development, and
 Torben Lund-Hansen, Ph.D., to Director, Process Development and Manufacturing.
     Dr. Curd joins Maxygen from VaxGen, Inc., a spin-off from Genentech, Inc.,
 where he held the position of Executive Vice President and was responsible for
 all aspects of product development for the company.  Previously at VaxGen,
 Dr. Curd held the position of Senior Vice President for Medical and Regulatory
 Affairs. In this capacity, he led and managed the clinical development of
 AIDSVAX, a preventative HIV/AIDS vaccine in late stage Phase III clinical
 trials, and directed the successful enrollment of these trials in
 North America, Europe and Thailand.  Throughout his tenure at VaxGen, Dr. Curd
 was an active member of the Executive Committee.
     Prior to joining VaxGen, Dr. Curd spent eight years at Genentech, most
 recently as Vice President of Clinical Development. During his years at
 Genentech, Dr. Curd led the clinical development of a broad range of drug
 candidates in oncology, immunology, allergy, pulmonology, and HIV vaccines
 including currently-marketed drugs Herceptin(R), Rituxan(R) and Actimmune(R)
 as well as Xolair, which is awaiting FDA approval.  Dr. Curd was also a member
 of Genentech's Research Review Committee and Clinical Review Committee.
 Before Genentech, Dr. Curd served as the Vice Chairman, Department of Medicine
 and head of the rheumatology division at the Scripps Clinic and Research
 Foundation.  During Dr. Curd's more than 15-year career at Scripps, he held a
 variety of positions including President of the Green Hospital of Scripps.
     Dr. Curd received his medical degree from Harvard Medical School and is
 the author or co-author of over 80 publications.
     "John joins Maxygen at an ideal time, as we ready our first
 pharmaceuticals for preclinical development and clinical trials," said
 Russell Howard, Ph.D., CEO of Maxygen. "John's wealth of experience in
 clinical development and success in bringing drugs to market has impacted
 countless patients' lives.  His successful track record in building clinical
 development infrastructure as well as designing and supervising clinical
 trials will be highly valuable as we move our pharmaceutical products forward
 through to commercialization."
     "I am delighted to join Maxygen, a company whose people and scientific
 innovations, I believe, are at least as well positioned to capture the promise
 of biotechnology as Genentech's in its early days," said Dr. Curd.  "I am
 looking forward to participating in creating the clinical infrastructure
 necessary to capture the significant potential of MolecularBreeding(TM) in
 human therapeutics."
     Dr. Glazer comes to Maxygen from Zealand Pharmaceuticals A/S, where as the
 Vice President of Development he was responsible for clinical and preclinical
 development of Zealand's pharmaceutical pipeline as well as regulatory affairs
 and quality assurance.  Prior to joining Zealand, Dr. Glazer held the position
 of Vice President of Clinical Development at Sunol Molecular Corp., and was
 previously the Director of Clinical and Scientific Affairs at Dade Behring,
 Inc.  Dr. Glazer also spent nine years with Novo Nordisk where he was
 responsible for the world-wide clinical development of NovoSeven(R) and
 tinzaparin (low molecular weight heparin), both currently marketed drugs in
 the U.S., European Union and Japan, as well as recombinant aprotinin. During
 the course of his career, Dr. Glazer also directed the development of three
 monoclonal antibodies and two peptide drug candidates that are in or about to
 enter Phase I clinical trials.  At Maxygen, Dr. Glazer will be involved in
 preclinical and clinical development, quality assurance and regulatory
 affairs.  Dr. Glazer received his medical degree from the University of
 Copenhagen.
     Dr. Lund-Hansen joins Maxygen from Novo Nordisk where he participated in
 review and identification of biopharmaceutical products for in-licensing.
 Also at Novo Nordisk, Dr. Lund-Hansen was in charge of global development of
 NovoSeven(R) and directed the process start-up of the NovoSeven(R)
 manufacturing facility.  He also directed the manufacture of tinzaparin and
 recombinant glucagon.  At Maxygen, Dr. Lund-Hansen will be responsible for
 process and product development as well as contract manufacturing.  Dr.
 Lund-Hansen holds a Ph.D. in biochemistry from the University of Copenhagen.
     "I am very pleased to welcome Drs. Curd, Glazer and Lund-Hansen to the
 Maxygen team.  These new appointments underscore Maxygen's commitment to
 establish a world-class clinical development infrastructure, one of our key
 goals for the year 2001," said Dr. Howard.
     Maxygen, Inc. headquartered in Redwood City, California, is focused on
 creating novel products using its integrated proprietary technologies for
 human therapeutics and industrial applications.  Maxygen's technologies bring
 together advances in molecular biology and protein modification to create
 novel biotechnology products.  Maxygen has strategic collaborations with
 leading companies including Lundbeck, Alk-Abello, Pfizer, Chevron, Novozymes,
 DSM, Hercules, Rio Tinto, DuPont and Syngenta as well as U.S.A. government
 funding from DARPA and NIST-ATP.
     Except for the historical information contained herein, this news release
 contains forward-looking statements including those relating to:  our ability
 to build a successful clinical development infrastructure; our ability to move
 our pharmaceutical products to commercialization and our ability to create
 novel biotechnology products.  Such statements involve risks and uncertainties
 that may cause results to differ materially from those set forth in these
 statements.  Among other things these risks and uncertainties include, but are
 not limited to:  inability to attract and retain qualified personnel; public
 acceptance of products obtained through genetic manipulation; the inherent
 uncertainties of biological research and our future ability to enter into
 and/or maintain research and commercialization collaborations.  These and
 other risk factors are more fully discussed in Maxygen's Annual Report on Form
 10-K for the year ended December 31, 2000, including under the caption "Risk
 Factors", and in Maxygen's other periodic reports filed with the SEC, all of
 which are available from Maxygen or from the SEC's website (www.sec.gov).
 Maxygen disclaims any obligation to update or revise any forward-looking
 statement contained herein to reflect any change in Maxygen's expectations
 with regard thereto or any change in events, conditions, or circumstances on
 which any such statement is based.  MolecularBreeding(TM) and Maxygen are
 U.S. trademarks used by Maxygen.  All other trademarks in this release are the
 property of their respective owners.
 
 

SOURCE Maxygen, Inc.
    REDWOOD CITY, Calif., April 12 /PRNewswire/ --
 Maxygen, Inc. (Nasdaq:   MAXY) today announced the appointment of John G. Curd,
 M.D., to the newly created position of Senior Vice President, Clinical
 Development.  Dr. Curd brings extensive protein pharmaceutical and vaccine
 development expertise to the company, and will oversee clinical development
 and medical affairs at Maxygen.  Maxygen also announced the appointments of
 Steven Glazer, M.D., to the position of Director, Clinical Development, and
 Torben Lund-Hansen, Ph.D., to Director, Process Development and Manufacturing.
     Dr. Curd joins Maxygen from VaxGen, Inc., a spin-off from Genentech, Inc.,
 where he held the position of Executive Vice President and was responsible for
 all aspects of product development for the company.  Previously at VaxGen,
 Dr. Curd held the position of Senior Vice President for Medical and Regulatory
 Affairs. In this capacity, he led and managed the clinical development of
 AIDSVAX, a preventative HIV/AIDS vaccine in late stage Phase III clinical
 trials, and directed the successful enrollment of these trials in
 North America, Europe and Thailand.  Throughout his tenure at VaxGen, Dr. Curd
 was an active member of the Executive Committee.
     Prior to joining VaxGen, Dr. Curd spent eight years at Genentech, most
 recently as Vice President of Clinical Development. During his years at
 Genentech, Dr. Curd led the clinical development of a broad range of drug
 candidates in oncology, immunology, allergy, pulmonology, and HIV vaccines
 including currently-marketed drugs Herceptin(R), Rituxan(R) and Actimmune(R)
 as well as Xolair, which is awaiting FDA approval.  Dr. Curd was also a member
 of Genentech's Research Review Committee and Clinical Review Committee.
 Before Genentech, Dr. Curd served as the Vice Chairman, Department of Medicine
 and head of the rheumatology division at the Scripps Clinic and Research
 Foundation.  During Dr. Curd's more than 15-year career at Scripps, he held a
 variety of positions including President of the Green Hospital of Scripps.
     Dr. Curd received his medical degree from Harvard Medical School and is
 the author or co-author of over 80 publications.
     "John joins Maxygen at an ideal time, as we ready our first
 pharmaceuticals for preclinical development and clinical trials," said
 Russell Howard, Ph.D., CEO of Maxygen. "John's wealth of experience in
 clinical development and success in bringing drugs to market has impacted
 countless patients' lives.  His successful track record in building clinical
 development infrastructure as well as designing and supervising clinical
 trials will be highly valuable as we move our pharmaceutical products forward
 through to commercialization."
     "I am delighted to join Maxygen, a company whose people and scientific
 innovations, I believe, are at least as well positioned to capture the promise
 of biotechnology as Genentech's in its early days," said Dr. Curd.  "I am
 looking forward to participating in creating the clinical infrastructure
 necessary to capture the significant potential of MolecularBreeding(TM) in
 human therapeutics."
     Dr. Glazer comes to Maxygen from Zealand Pharmaceuticals A/S, where as the
 Vice President of Development he was responsible for clinical and preclinical
 development of Zealand's pharmaceutical pipeline as well as regulatory affairs
 and quality assurance.  Prior to joining Zealand, Dr. Glazer held the position
 of Vice President of Clinical Development at Sunol Molecular Corp., and was
 previously the Director of Clinical and Scientific Affairs at Dade Behring,
 Inc.  Dr. Glazer also spent nine years with Novo Nordisk where he was
 responsible for the world-wide clinical development of NovoSeven(R) and
 tinzaparin (low molecular weight heparin), both currently marketed drugs in
 the U.S., European Union and Japan, as well as recombinant aprotinin. During
 the course of his career, Dr. Glazer also directed the development of three
 monoclonal antibodies and two peptide drug candidates that are in or about to
 enter Phase I clinical trials.  At Maxygen, Dr. Glazer will be involved in
 preclinical and clinical development, quality assurance and regulatory
 affairs.  Dr. Glazer received his medical degree from the University of
 Copenhagen.
     Dr. Lund-Hansen joins Maxygen from Novo Nordisk where he participated in
 review and identification of biopharmaceutical products for in-licensing.
 Also at Novo Nordisk, Dr. Lund-Hansen was in charge of global development of
 NovoSeven(R) and directed the process start-up of the NovoSeven(R)
 manufacturing facility.  He also directed the manufacture of tinzaparin and
 recombinant glucagon.  At Maxygen, Dr. Lund-Hansen will be responsible for
 process and product development as well as contract manufacturing.  Dr.
 Lund-Hansen holds a Ph.D. in biochemistry from the University of Copenhagen.
     "I am very pleased to welcome Drs. Curd, Glazer and Lund-Hansen to the
 Maxygen team.  These new appointments underscore Maxygen's commitment to
 establish a world-class clinical development infrastructure, one of our key
 goals for the year 2001," said Dr. Howard.
     Maxygen, Inc. headquartered in Redwood City, California, is focused on
 creating novel products using its integrated proprietary technologies for
 human therapeutics and industrial applications.  Maxygen's technologies bring
 together advances in molecular biology and protein modification to create
 novel biotechnology products.  Maxygen has strategic collaborations with
 leading companies including Lundbeck, Alk-Abello, Pfizer, Chevron, Novozymes,
 DSM, Hercules, Rio Tinto, DuPont and Syngenta as well as U.S.A. government
 funding from DARPA and NIST-ATP.
     Except for the historical information contained herein, this news release
 contains forward-looking statements including those relating to:  our ability
 to build a successful clinical development infrastructure; our ability to move
 our pharmaceutical products to commercialization and our ability to create
 novel biotechnology products.  Such statements involve risks and uncertainties
 that may cause results to differ materially from those set forth in these
 statements.  Among other things these risks and uncertainties include, but are
 not limited to:  inability to attract and retain qualified personnel; public
 acceptance of products obtained through genetic manipulation; the inherent
 uncertainties of biological research and our future ability to enter into
 and/or maintain research and commercialization collaborations.  These and
 other risk factors are more fully discussed in Maxygen's Annual Report on Form
 10-K for the year ended December 31, 2000, including under the caption "Risk
 Factors", and in Maxygen's other periodic reports filed with the SEC, all of
 which are available from Maxygen or from the SEC's website (www.sec.gov).
 Maxygen disclaims any obligation to update or revise any forward-looking
 statement contained herein to reflect any change in Maxygen's expectations
 with regard thereto or any change in events, conditions, or circumstances on
 which any such statement is based.  MolecularBreeding(TM) and Maxygen are
 U.S. trademarks used by Maxygen.  All other trademarks in this release are the
 property of their respective owners.
 
 SOURCE  Maxygen, Inc.